Conference

Agenda



EET time
09:30 -10:20 Welcome and Opening Speeches
Conference Moderator Eleni Manitsa, former Member of the Medicines Negotiations Committee
Ioannis Kotsiopoulos, Secretary General of Health Services, Ministry of Health, Greece
“HTA implementation in Greece: A 3 years’ experience from the industry perspective”
Olympios Papadimitriou, President, Hellenic Association of Pharmaceutical Companies (SFEE)
Vasilios Pentafragas, Executive Director, Panhellenic Pharmaceutical Association (PEF)
Agata Jakoncic, President, Pharma Innovation Forum (PIF)
“HTA implementation in Greece: Patients’ Association perspective”
Georgios Tsiakalakis, Director, Hellenic Patients Association (EAE)

10:20 – 11:40

SESSION 1 | IMPLEMENTING HEALTH TECHNOLOGY ASSESSMENT IN GREECE: CHALLENGES AND OPPORTUNITIES

Moderator Kyriakos Souliotis, Professor of Health Policy at the University of Peloponnese
“Challenges, hurdles, and opportunities for an efficient HTA implementation in Greece”
Flora Bacopoulou, President of the HTA Committee, Associate Professor of Pediatrics – Adolescent Medicine, National and Kapodistrian University of Athens
“Progress of the Medicines Negotiation committee operations and the impact on pharmaceutical budgets”
Dimitrios Filippou, President of the National Medicines Organization (EOF), President of the Medicines Negotiations Committee, Assistant Professor of Anatomy, National and Kapodistrian University of Athens
“A proposal for the procedures and organization of health technology assessment in Greece”
Kostas Athanasakis, Health Economist, University of West Attica
“Elements and Observations from HTA and Negotiation committee operations”
Panos Stafylas, MD, MSc, PhD, Cardiologist / HTA Consultant, Scientific Director of HealThink PC, Greece
Discussion – Q&A
11:40 – 12:15 Expo – Networking Break

12:15 – 14:15

SESSION 2 | ASSESSING THE VALUE OF THE NEW TECHNOLOGIES AND THE ROLE OF EVIDENCE QUALITY

Moderator Yannis Yfantopoulos, Professor of Health Economics and Social Policy, Department of Political Science and Public Administration, National and Kapodistrian University of Athens
Introductory Speech “Assessing the added value of new technologies”
Maria Kalogeropoulou, HTA Senior Consultant, IQVIA
  “The need for innovative HTA methods for more complex and personalized medicine”
Wim Goettsch, PhD Associate Professor of HTA, Utrecht Centre for Pharmaceutical Policy
“Scientific evidence in assessing different technologies” 
Aris Angelis, Assistant Professor in Health Economics at London School of Hygiene and Tropical Medicine (LSHTM), Visiting Fellow, Department of Health Policy at LSE
“Identifying the right treatment for the right patient: reimbursement of biomarkers and genomic sequencing”
Angeliki Angeli, Chief Portfolio Value Officer, Roche
“Do we need special processes to appraise treatments for rare diseases?”
Elena Nicod, Associate Director at Dolon, PhD Centre for Research on Health and Social Care Management (CERGAS), Bocconi University
“Tapping into resources to strengthen the Value of Evidence for HTA Submissions in Greece”
Myrsini Ouzounelli, MD MBA MPH. CEO, MYO Health
Discussion – Q&A

14:15 – 15:30

SPOTLIGHT SESSION ON THE FUTURE OF HTA

Moderator Mary Geitona, BSc, Ph.D. Professor in Health Economics, University of Peloponnese
  “The future of HTA relies on the Member state cooperation” 
Panos Kanavos, PhD, Associate Professor, Deputy Director, LSE Health, Department of Social Policy, London School of Economics
“Priority setting, Horizon scanning and joint assessments/ negotiations to ensure sustainable access to innovative medicines: The BENELUXA experience” 
Francis Arickx, Advisor at RIZIV-INAMI, Country Coordinator of Belgium for the Beneluxa Initiative
“European collaborations on patient access to medicines – Lessons learned and implications for national pricing policies such as external price referencing”
Sabine Vogler, Head of the Pharmacoeconomics Department, Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Austrian Public Health Institute
Discussion – Q&A
15:30 – 16:15 Expo – Networking Break

16:15 – 17:30

SESSION 3 | FUNDING AND FINANCING MODELS FOR NEW INNOVATIVE TREATMENTS: DIFFERENCES AND SIMILARITIES VS CURRENT PRICING MODELS

Moderator Elpida Pavi, Professor, Department of Public Health Policy, Dean of School of Public Health, University of West Attica
“Gene Therapies: Is Europe Ready to Value and Reimburse the Next Medical Frontier”
Michael Drummond, MCom, DPhil, Professor of Health Economics, University of York, United Kingdom
“What is the future of managed entry agreements in the digital health era?”
Katarzyna Kolasa, Professor Kozminski University, Head of Health Economics and Healthcare Management Division
“Budget impact and thresholds as barriers for funding innovation”
Athanasios Vozikis, Associate Professor, Director of the Laboratory of Health Economics and Management, University of Piraeus, Department of Economics
“Risk sharing and time to Access for Innovation”
Ilias Kontoudis, Head of Market Access, Bayer Hellas
Discussion – Q&A
17:30 Conclusions

Contact us


Sponsorships & Registrations
Chrysoula Kordouli, Τ: +30 210 6617777 (ext. 204), +30 6946236795, E: [email protected]

Content
Natalia Toubanaki, T: +30 210 6617 777 (ext. 289), +306947936708, E: [email protected]
Renata Valsami, T: +30 210 6617 777 (ext. 147), +30 6944940915, E: [email protected]

BOUSSIAS

  338. Kleisthenous Str. 15344, Gerakas, Attiki, Greece
  +30 210 6617777
  +30 210 6617778
  www.boussias.com